Please ensure Javascript is enabled for purposes of website accessibility

Why BioNTech Leaped Nearly 7% Higher Today

By Eric Volkman - May 14, 2021 at 6:16PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A fascinating new finding put some juice into the biotech's stock.

What happened

Model coronavirus stock BioNTech (BNTX -7.54%) shot 6.6% higher Friday. This was due to encouraging news about the coronavirus vaccine BNT162b2, which it developed with Pfizer (PFE 0.61%). A big pronouncement by a major health authority also helped.

So what

In a 175-participant study of elderly patients who had received both doses of the two-jab BNT162b2, British researchers found that it actually induces a stronger antibody response when the two shots are spaced further apart than recommended -- 12 weeks rather than the three of official guidance.

Gloved hands holding a vial of vaccine.

Image source: Getty Images.

The U.K. scientists found that when the gap was widened to 12 weeks, the study's participants experienced antibody responses that were 3.5 times higher than those of the three-weekers. 

While more work certainly needs to be done on this phenomenon, it's yet another indication that the vaccine is highly effective. As such, it'll remain a leading go-to solution for beating back the coronavirus pandemic. 

Compounding that positive development, the U.S. Centers for Disease Control and Prevention (CDC) Thursday updated guidance for fully vaccinated individuals. The CDC now advises that such people can participate in a wide range of activities without wearing a mask.

Now what

The CDC's update is less obviously beneficial for BioNTech than the study's findings. It's very possible that those previously reluctant to get their shots will do so with the inducement of eventually being able to go maskless. Combined, these developments point to a strong and sustained future for the biotech and its key product.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

BioNTech SE Stock Quote
BioNTech SE
$169.30 (-7.54%) $-13.81
Pfizer Inc. Stock Quote
Pfizer Inc.
$49.57 (0.61%) $0.30

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/09/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.